Eppendorf Grows Faster than the Market During the First Half of 2017
During the fi rst half of 2017, the Eppendorf Group achieved group sales of €327.9 million (prior-year period: €305.5 million). At 7.3% (6.6% when adjusted for currency effects), growth in sales lay above average market growth in the life science industry. Income from operations (EBIT) climbed 9.1% to €63.2 million (prior-year period: €58.0 million), amounting to an EBIT margin of 19.3% (prior year: 19.0%). All of the Eppendorf Group’s market regions and product groups contributed to this positive overall development.
Thomas Bachmann, President & CEO of Eppendorf AG, was very pleased at
this positive development: “The mid-year result shows that we outperformed the market during the fi rst half of this year. We are currently working on digitalising our product portfolio and the connectivity of our devices with our new generation of networked products, which we launched on the market during the fi rst six months of the year. We are assuming that our business will continue to develop positively overall for the whole year 2017 and we expect growth to be higher than the industry average.”
43673pr@reply-direct.com
Double Digit Growth Reported at CPhI China
CPhI and P-MEC China, organised by UBM EMEA, UBM Sinoexpo and China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), closed in June 2017 with a very successful show, reporting positive outlook for further Chinese pharmaceutical market development. Since 2016 CPhI China has experienced a 14% growth in overall visits and a 12% growth in overseas visits, a remarkable achievement for a mature market with 17 pervious editions behind it.
The event, featuring 2,800+ exhibiting companies covering the entire supply chain, acts as an accurate barometer of the industry’s overall growth patterns and future developments. Two major trends to emerge from Asia’s largest pharma event were the increased interest and promotion of
‘intelligent manufacturing’ systems as
well as ‘green manufacturing’ approaches. The former emphasised a rapid shift within China’s industry towards advanced facilities and product classes. However, the latter is a particularly notable change in light of the country’s general reputation, and the fi rst ever ‘China Pharma Environmental Forum’ was an integral feature of this year’s exhibition.
Another major development in 2017 was the introduction of the fi rst edition of the CPhI China Pharma Week, which was a direct response to China’s increased internationalisation. Across the entire week, CPhI and P-MEC China attendees had the opportunity to experience richer content than in any other previous edition. To mention a few: Plant visits in leading R&D and innovation companies, CPhI China River Cruise Networking dinner on Huangpu River that held over 250
Asia’s infl uential pharmaceutical trading platform
overseas and domestic attendees, the CPhI Pharma Business International Program to help overseas companies solve problems they encounter when entering the Chinese market and many more.
As part of the CPhI China Pharma week, the show saw the launch of the ‘Bluebook on Internationalization of China’s Pharmaceutical Industry’, listing the largest Chinese companies operating internationally, and ‘The 2017 Awards for Top 100 Internationalized Pharmaceutical Companies in China’. Both infl uential regional lists that review and document the country’s most prominent companies.
Finally, 2017 saw the arrival of another global trend sweeping through pharma with the fi rst ever CPhI Women in Leadership Forum in China, which featured high level debates on how to advance female executive potential contributing to the fast development of Pharmaceutical industry in the country.
In total, 55,020 visits were recorded over the three day Shanghai event, with 10,126 visits from international attendees, including representatives from more than 120 different countries, covering an enormous 165,000m2
of exhibition space at the
Shanghai New International Expo Centre, which makes it the biggest edition of CPhI and P-MEC
China to date.
Rutger Oudejans, Brand Director Pharma at UBM said: “CPhI China has grown to be the single most infl uential meeting point for pharma suppliers and customers, and this year we observed a record number of international attendees and over 55,000 visits in total. The pharma economy has diversifi ed rapidly in the last few years and new markets are emerging in bio and fi nal dosage forms. In addition to the ingredients sector, which represents some 40% of global production. This year’s event was especially signifi cant as we increased the range of insights and analysis across the changing business and regulatory environment. With sessions held on everything from the MAH pilot to formulation development strategies and international distribution. Next year we expect even stronger growth as domestic pharma economy cements its number 2 status and exports of new forms grow exponentially.
CPhI and P-MEC China will return with its 18th edition again in 2018. The event will be held from 20 - 22 June 2018 in Shanghai New International Expo Centre, alongside the 2nd CPhI China Pharma Week edition.
43630pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128
